ASCO 2026 Archives - SOHO Insider

Skip to content

FDA grants fast track designation to STX-0712 in relapsed or refractory CMML
Novel germline JAK2 mutation linked to progression to MF in MPN
Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial
ERNEST-3 analysis characterizes prevalence of cytopenic MF and treatment trends
Study identifies 4 clinically distinct myelofibrosis subtypes that have different survival prognoses

Insider Reader Survey

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial

Cellular Therapy

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial

Leukemia

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial

Lymphoma

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial

Multiple Myeloma

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial

Myelodysplastic Syndromes

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

June 18, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Meetings / Conferences ASCO 2026

ASCO 2026

News and highlights from the 2026 ASCO meeting in Chicago.

ASCO 2026 Meetings / Conferences Myeloproliferative Neoplasms Primary Myelofibrosis Video Interviews

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial

by SOHO Insider Editors
June 16, 2026
0 Comments

EHA 2026 ASCO 2026 Meetings / Conferences Myeloproliferative Neoplasms

Patients with myelofibrosis and anemia respond to antihemojuvelin drug

by Emily Hayes
June 12, 2026
0 Comments

ASCO 2026 Meetings / Conferences Myeloproliferative Neoplasms News

John Mascarenhas, MD, discusses the phase 3 SENTRY trial

by SOHO Insider Editors
June 11, 2026
0 Comments

Doctor at laptop

ASCO 2026 Acute Myeloid Leukemia News

Which AML patients get lasting benefit from olutasidenib?

by Emily Hayes
June 9, 2026
0 Comments

Dr. Marc Hoffman

ASCO 2026 Lymphoma Aggressive B-Cell Lymphomas Meetings / Conferences News

Dr. Marc Hoffman discusses results from the GOLSEEK-1 trial of golcadomide in frontline ABCL

by SOHO Insider Editors
June 9, 2026
0 Comments

Microscope in AI virtual pattern

ASCO 2026 Cellular Therapy Multiple Myeloma News

Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials

by Patrick Daly
June 8, 2026
0 Comments

ASCO 2026 Trending now Multiple Myeloma SOHO Insider Podcast

Dr. Roberto Mina on the pivotal phase 3 MajesTEC-9 trial in multiple myeloma

by SOHO Insider Editors
June 5, 2026
0 Comments

ASCO 2026 Cellular Therapy News

Data support COVID-19 vaccination in patients receiving CAR-T therapy

by Emily Hayes
June 4, 2026
0 Comments

ASCO 2026 Trending now Meetings / Conferences Multiple Myeloma News

Dr. Hans Lee on MRNA-2808 in relapsed or refractory multiple myeloma

by SOHO Insider Editors
June 4, 2026
0 Comments

Doctor Inspecting Samples in Lab

ASCO 2026 Aggressive B-Cell Lymphomas News

Largest study of rare HHV8+ DLBCL identifies risk factors associated with poor survival

by Kerri Fitzgerald
June 4, 2026
0 Comments

1
2

Top Categories

Cellular Therapy

74

Leukemia

114

Lymphoma

128

Multiple Myeloma

98

Myelodysplastic Syndromes

39

Myeloproliferative Neoplasms

28

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Largest study of rare HHV8+ DLBCL identifies risk factors associated with poor survival

Cellular Therapy

Largest study of rare HHV8+ DLBCL identifies risk factors associated with poor survival

Leukemia

Largest study of rare HHV8+ DLBCL identifies risk factors associated with poor survival

Lymphoma

Largest study of rare HHV8+ DLBCL identifies risk factors associated with poor survival

Multiple Myeloma

Largest study of rare HHV8+ DLBCL identifies risk factors associated with poor survival

Myelodysplastic Syndromes

Largest study of rare HHV8+ DLBCL identifies risk factors associated with poor survival

Myeloproliferative Neoplasms

Subscribe

Recent Posts

FDA stamp on white paper

FDA grants fast track designation to STX-0712 in relapsed or refractory CMML

Young scientists conducting research investigations in a medical laboratory, a researcher in the foreground is using a microscope

Novel germline JAK2 mutation linked to progression to MF in MPN

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.